LAUSR

The recently published work of Cappelli et al raises the practical question: What should we use for imaging of suspected transthyretin cardiac amyloidosis (ATTR)? It concluded that Tc-hydroxymethylene diphosphonate (HDP) was sufficiently accurate for diagnosis of ATTR. The right answer to this question has particularly become more relevant currently with the emergence of effective treatment options for ATTR amyloidosis such as tafamidis, patisiran, and inotersen. Previously though, this was more of an academic question given the lack of therapeutic options with a high morbidity and mortality.